Abstract 4069: FGFR2 expression and mutation are rare in papillary renal cell carcinoma.

Abstract

Abstract Papillary renal cell carcinoma (pRCC) is the second most common type of renal cell carcinoma (RCC). Fibroblast growth factor receptor (FGFR) 1 signaling has been implicated to play a role in RCC (Tsimafeyeu et al. ASCO meeting 2010). We evaluated expression and mutational activation of FGFR2 as a potential target for therapy of pRCC. Formalin-fixed, paraffin-embedded specimens of removed 71 primary tumors from untreated pRCC patients were evaluated by immunohistochemistry with FGFR2 antibody. FGFR2 mutations were assessed by PCR and direct sequencing, with DNA obtained from 62 paraffin-embedded pRCC samples. Expression of FGFR2 was observed in 8.5% of primary pRCC (6/71). Intensity was 3+ in all cases. 2 of 71 (3%) patients had nuclear FGFR2 expression. FGFR2 S252W mutation was detected at low frequency (1/62, 1.6%) in pRCC (type I). No N549K mutation was detected in pRCC (0/43). FGFR2 expression and mutation are rare across papillary types of RCC. This study was supported by Mr. Sergey Kartashov. Citation Format: Ilya V. Tsimafeyeu, Nigel Wynn, Marat Gordiyev, Alfia Khasanova. FGFR2 expression and mutation are rare in papillary renal cell carcinoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4069. doi:10.1158/1538-7445.AM2013-4069